Woman with safety glasses
Woman with safety glasses

Our Pipeline

An overview of the clinical studies on our own drug candidates and the most advanced clinical programs of our partners.

Our Pipeline

Latest Update: February 2024

MorphoSys' Clinical Programs

Compound / Brand name
Indication
NCT
Pelabresib
Target BET Inhibitor
Myelofibrosis (MANIFEST-2)
Myelofibrosis / Essential Thrombocythemia (MANIFEST)
Tulmimetostat
Target EZH1/EZH2 Dual Inhibitor
Advanced Solid Tumors / Hematologic Malignancies

Selection of our Partners’ Clinical Programs

Compound / Brand name
Partner
Program
Compound / Brand name
Ianalumab (VAY736)
Partner
Novartis
Program

Ianalumab (VAY736) is a fully human IgG1/k mAb with a dual mode of action targeting B-cell lysis and BAFF-R blockade that is being investigated by Novartis in several indications including lupus nephritis (LN), Sjögren’s, systemic lupus erythematosus (SLE), immune thrombocytopenia (1L and 2L ITP), and warm autoimmune hemolytic anemia (wAIHA). Ianalumab is also in Phase 2 clinical development in autoimmune hepatitis (AIH).

Compound / Brand name
Abelacimab (MAA868)
Partner
Anthos Therapeutics
Program

Abelacimab (MAA868) is an antibody directed against Factor XI that is being investigated by Anthos Therapeutics in two complementary FDA fast track designated Phase 3 clinical studies in cancer-associated thrombosis (CAT) for the prevention of venous thromboembolism (VTE) and in one Phase 3 study in high-risk patients with atrial fibrillation (AF).

Compound / Brand name
Setrusumab (BPS804/UX143)
Partner
Mereo Biopharma and Ultragenyx
Program

Setrusumab (BPS804/UX143) is an antibody directed against sclerostin that is currently being investigated by Ultragenyx and Mereo BioPharma in a Phase 3 clinical study for the treatment of osteogenesis imperfecta.

Compound / Brand name
Bimagrumab
Partner
Lilly
Program

Bimagrumab is currently being investigated by Lilly in Phase 2b study as a novel treatment for obesity.

Compound / Brand name
Felzartamab
Partner
HIBIO-I-Mab
Program

Felzartamab is a therapeutic human monoclonal antibody directed against CD38. Human Immunology Biosciences, Inc. (HI-Bio) obtained exclusive rights to develop and commercialize felzartamab across all indications worldwide, with the exception of Greater China. HI-Bio is evaluating felzartamab for patients with two renal autoimmune diseases, anti-PLA2R antibody-positive membranous nephropathy (NewPLACE trial) and Immunoglobulin A Nephropathy (IGNAZ trial). I-Mab Biopharma holds the exclusive regional rights to develop and commercialize felzartamab in Greater China and is studying felzartamab in relapsed/refractory multiple myeloma.

Compound / Brand name
NOV-8 (CMK389)
Partner
Novartis
Program

NOV-8 (CMK389) is being investigated by Novartis for the treatment of pulmonary sarcoidosis (Phase 2) and severe atopic dermatitis (also Phase 2).

Compound / Brand name
MOR210/TJ210/HIB210
Partner
HIBIO-I-Mab
Program

MOR210/TJ210/HIB210 is a human antibody directed against C5aR1, the receptor of the complement factor C5a, currently in Phase 1 clinical development. Human Immunology Biosciences (HI-Bio) obtained exclusive worldwide rights to develop and commercialize MOR210 across all indications worldwide, with the exception of Greater China and South Korea. I-Mab Biopharma holds the exclusive rights for MOR210 in Greater China and South Korea. 

MORPHOSYS’ CLINICAL PROGRAMS

Pelabresib

Pelabresib

Pelabresib is an investigational BET inhibitor being studied in myelofibrosis and other myeloid diseases.

Tulmimetostat

Tulmimetostat

Tulmimetostat is an investigational next-generation dual EZH2/EZH1 inhibitor being explored in solid tumors and lymphomas.